

Biography	xxv
Section Editors	xxvii
Contributors	xxix
Preface to the First Edition	xxxv
Preface to the Second Edition	xxxvii
Preface to the Third Edition	xxxix

Part I General Aspects of Medicinal Chemistry

Section Editor: Hugo Kubinyi

1. A History of Drug Discovery	3
<i>François Chast</i>	
I. Introduction	4
A. The renewal of chemistry	4
B. The dawn of the organic chemistry crosses the birth of biology	5
II. Two Hundred Years of Drug Discoveries	6
A. Pain killers: best-sellers and controversies	6
B. Giving back the heart its youth	10
C. Fight against microbes and viruses	15
D. Drugs for immunosuppression	24
E. Contribution of chemists to the fight against cancer	26
F. Drugs for endocrine disorders	30
G. Anti-acid drugs	34
H. Lipid lowering drugs	35
I. From neurotransmitters to receptors	37
J. Drugs of the mind	41
III. Considerations on Recent Trends in Drug Discovery	49
A. From genetics to DNA technology	49
B. Hopes and limits for drug hunting	52
References	55
2. Medicinal Chemistry: Definitions and Objectives, Drug Activity Phases, Drug Classification Systems	63
<i>Peter Imming</i>	
I. Definitions and Objectives	63
A. Medicinal chemistry and related disciplines and terms	63
B. Drugs and drug substances	64
C. Stages of drug development	64
II. Drug Activity Phases	66
A. The pharmaceutical phase	66
B. The pharmacokinetic phase	66

C. The pharmacodynamic phase	67
D. The road to successful drug development?	67
III. Drug Classification Systems	67
A. Classification by target and mechanism of action	68
B. Other classification systems	70
References	71
3. Measurement and Expression of Drug Effects	73
<i>Jean-Pierre Nowicki and Bernard Scatton</i>	
I. Introduction	73
II. <i>In Vitro</i> Experiments	75
A. Binding studies	75
B. Ligand–receptor interaction-induced functional effects	76
C. Allosteric interaction	78
D. Expression of functional effects for targets other than GPCRS	79
E. Cellular and tissular functional responses	79
III. <i>Ex Vivo</i> Experiments	81
IV. <i>In Vivo</i> Experiments	82
References	83
4. Molecular Drug Targets	85
<i>Jean-Pierre Gies and Yves Landry</i>	
I. Introduction	86
A. How many drug targets for how many drugs?	86
B. From the drug target to the response of the organism	86
C. Drug binding, affinity and selectivity	87
D. Various ligands for a single target	87
II. Enzymes as Drug Targets	88
A. Targeting human enzymes	88
B. Targeting enzymes selective of invading organisms	89
III. Membrane Transporters as Drug Targets	89
A. Established drug targets among membrane transporters	89
B. Progress in the pharmacological control of membrane transporters	89
IV. Voltage-Gated Ion Channels as Drug Targets	90
A. Voltage-gated sodium channels (Na _v channels)	90
B. Voltage-gated calcium channels (Ca _v channels)	91
C. Potassium channels	91
V. Non-Selective Cation Channels as Drug Targets	92
VI. Direct Ligand-Gated Ion Channels (Receptors with Intrinsic Ion Channel)	93
A. P2X-ATP receptors	94
B. Glutamate-activated receptors	94
C. The “Cys-loop receptor superfamily”	95
VII. Receptors with Intrinsic Enzyme Activity	95
A. Receptors with guanylate cyclase activity	95
B. Receptors with serine/threonine kinase activity	96
C. Receptors with tyrosine kinase activity	96
VIII. Receptors Coupled to Various Cytosolic Proteins	97
A. Receptors coupled to the cytosolic tyrosine kinase JAK	97
B. Receptors coupled to the cytosolic Src, Zap70/Syk and Btk tyrosine kinases (immunoreceptors)	97
C. Receptors coupled to the cytosolic serine/threonine kinase IRAK	98
D. Receptors coupled to caspases and to NFκB	98
E. Receptors of the cellular adhesion	99
IX. G-Protein-Coupled Receptors	99
A. How many druggable GPCRS?	100

B. Diversity of G-proteins	101
C. Diversity of GPCR-elicited signaling and related drug targets	101
X. Nuclear Receptors As Drug Targets	103
References	104

5. Drug Targets, Target Identification, Validation and Screening 106

Kenton H. Zavitz, Paul L. Bartel and Adrian N. Hobden

I. Introduction	106
II. Improving the Resolution of Disease Etiology	107
III. Biopharmaceutical Therapies	108
A. Passive immunotherapy	108
IV. Drug Target Identification	109
A. Rare mutations leading to generalized therapies	109
B. Mining the proteome	109
C. Yeast two-hybrid systems	110
D. RNA interference	111
V. Hit-to-Lead	113
A. Cell-based screening	113
B. Intracellular receptors	113
C. Intracellular enzymes	115
D. G-protein-coupled receptors	115
E. Transgenic animals	117
F. Drug metabolism	118
G. Toxicology	118
VI. Clinical Biomarkers	119
VII. Conclusions	119
References	119

Part II Lead Compound Discovery Strategies

Section Editor: John R. Proudfoot

123

6. Strategies in the Search for New Lead Compounds or Original Working Hypotheses 125

Camille G. Wermuth

I. Introduction	125
A. Hits and leads	125
B. The main hit or lead finding strategies	126
II. First Strategy: Analog Design	126
A. Typical examples	126
B. The different categories of analogs	127
C. Pros and cons of analog design	128
III. Second Strategy: Systematic Screening	129
A. Extensive screening	129
B. Random screening	129
C. High-throughput screening	130
D. Screening of synthesis intermediates	131
E. New leads from old drugs: The SOSA approach	132
IV. Third Strategy: Exploitation of Biological Information	134
A. Exploitation of observations made in humans	134
B. Exploitation of observations made in animals	137
C. Exploitation of observations made in the plant kingdom and in microbiology	137
V. Fourth Strategy: Planned Research and Rational Approaches	138
A. L-DOPA and parkinsonism	138

IV. Creation and Analysis of FBDD Libraries	234
A. General evaluation and analysis	234
B. Computational approaches	235
C. Use of primary data: sprouting and merging to create secondary libraries	235
V. Nuclear Magnetic Resonance	235
A. 1D (ligand-based) screening	235
B. Example	236
C. 2D (protein-based) screening	237
VI. X-ray Crystallography	237
A. General principles and limitations	237
B. Examples	238
VII. Other Biophysical and Biochemical Screening Methods	238
A. Substrate activity screening	238
B. <i>In situ</i> click chemistry	239
C. SPR spectroscopy	239
D. SAR by mass spectroscopy	239
VIII. Methods for Fragment Hit Follow-Up	239
A. How to best reduce false positives (NMR, MS) and false negatives (X-ray)	239
B. Isothermal and differential titration calorimetry and further secondary analysis	240
IX. Trends for the Future	240
References	241

12. Lead-Likeness and Drug-Likeness 244

Alex Polinsky

I. Introduction	244
II. Assessing “Drug-Likeness”	245
A. Avoiding known threats	245
B. Mimicking known drugs	247
C. Direct property prediction	249
III. Selecting Better Leads: “Lead-Likeness”	250
A. What is a “high-quality” lead compound?	250
B. Designing “lead-like” libraries for biochemical screening	251
IV. Conclusion	253
References	253

13. Web Alert: Using the Internet for Medicinal Chemistry 255

David Cavalla

I. Introduction	255
II. Blogs	256
III. Wikis	257
A. RSS information feeds	257
IV. Compound Information	257
A. Chemspider	257
B. The NIH Roadmap and PubChem	258
C. ChemBank	258
V. Biological Properties of Compounds	258
A. Prediction of biochemical properties	259
B. Molecular datasets	259
C. Information on metabolic properties	260
VI. Drug Information	260
A. DrugBank	260
VII. Physical Chemical Information	261
VIII. Prediction and Calculation of Molecular Properties	261
IX. Chemical Suppliers	263

X.	Chemical Synthesis	264
XI.	Chemical Software Programs	263
	A. Chemical drawing and viewing software	264
	B. Various chemoinformatics software	265
	C. Datasets for virtual screening	266
XII.	Analysis	267
XIII.	Chemical Publications	267
	A. Journals	267
	B. Open access	268
	C. Theses	268
XIV.	Patent Information	269
	A. Japanese patents	270
XV.	Toxicology	270
XVI.	Metasites and Technology Service Provider Databases	272

Part III Primary Exploration of Structure–Activity Relationships

Section Editor: Camille G. Wermuth

273

14.	Molecular Variations in Homologous Series: Vinylogues and Benzologues	275
	<i>Camille G. Wermuth</i>	
	I. Homologous Series	275
	A. Definition and classification	275
	B. Shapes of the biological response curves	277
	C. Results and interpretation	278
	II. Vinylogues and Benzologues	283
	A. Applications of the vinylogy principle	283
	B. Comments	287
	References	287
15.	Molecular Variations Based on Isosteric Replacements	290
	<i>Paola Ciapetti and Bruno Giethlen</i>	
	I. Introduction	290
	II. History: Development of the Isosterism Concept	291
	A. The molecular number	291
	B. The isosterism concept	292
	C. The notion of pseudoatoms and Grimm's hydride displacement law	293
	D. Erlenmeyer's expansion of the isosterism concept	293
	E. Isosterism criteria: Present conceptions	293
	F. The bioisosterism concept: Friedman's and Thorber's definitions	294
	III. Currently Encountered Isosteric and Bioisosteric Modifications	294
	A. Replacement of univalent atoms or groups	294
	B. Interchange of divalent atoms and groups	294
	C. Interchange of trivalent atoms and groups	296
	D. Ring equivalents	297
	E. Groups with similar polar effects: functional equivalents	303
	F. Reversal of functional groups	320
	IV. Scaffold Hopping	323
	A. Successful examples of serendipitous scaffold hopping	323
	B. Scaffold hopping and virtual screening	325
	V. Analysis of the Modifications Resulting from Isosterism	326
	A. Structural parameters	327
	B. Electronic parameters	327
	C. Solubility parameters	327
	D. Anomalies in isosterism	328

VI. Minor Metalloids-Toxic Isosters	330
A. Carbon–silicon bioisosterism	330
B. Carbon–boron isosterism	331
C. Bioisosteres involving selenium	333
References	334
16. Ring Transformations	343
<i>Christophe Morice and Camille G. Wermuth</i>	
I. Introduction	343
II. Analogical Approaches	343
A. Analogy by ring opening: open-chain analogs	343
B. Analogy by ring closure	345
C. Other analogies	349
III. Disjunctive Approaches	354
A. Cocaine-derived local anesthetics	355
B. Morphinic analgesics	355
C. Dopamine autoreceptor agonists	355
D. CCK antagonists	355
IV. Conjunctive Approaches	356
A. Dopaminergic antagonists	356
B. Glutamate NMDA and AMPA receptor antagonists	358
C. Norfloxacin analogs	359
D. Melatonin analogs	360
V. Conclusion	360
References	360
17. Conformational Restriction and/or Steric Hindrance in Medicinal Chemistry	363
<i>André Mann</i>	
I. Introduction	363
A. Theoretical points	364
B. On constrained analogs	366
C. On conformational analysis	367
D. On the nature of Steric effects	368
E. Rigid compounds and bioavailability	368
II. Case studies	368
A. Bradykinin	368
B. Allylic constraints for inducing conformational rigidity	369
C. Diversity-Oriented Synthesis	371
D. Epibatidine bioactive conformation	371
E. Ligands for the Hepatitis C virus	372
F. Nociceptin	374
G. Opioid receptors ligands	374
H. Peptidomimetics for SH2 domains	375
III. Summary and Outlook	377
References	378
18. Homo and Heterodimer Ligands the Twin Drug Approach	380
<i>Jean-Marie Contreras and Wolfgang Sippl</i>	
I. Introduction	380
II. Homodimer and Symmetrical Ligands	383
A. Symmetry in nature	383
B. Homodimers as receptors ligands	383
C. Homodimers as enzyme inhibitors	387

D. Homodimers as DNA ligands	390
E. Homodimers of pharmacological interest	390
III. Heterodimer and Dual Acting Ligands	391
A. Hybrid molecules as ligands of two different receptors	391
B. Hybrids as enzymes inhibitors	394
C. Hybrids acting at one receptor and one enzyme	398
D. Other examples of dual acting drugs	400
IV. Binding Mode Analysis of Identical and Non-identical Twin Drugs	401
A. Identical and non-identical twin drugs interacting with two adjacent binding sites located on the same macromolecule	403
B. Identical twin drugs interacting with two similar binding sites located on different monomers of the same macromolecule	405
C. Identical and non-identical twin drugs interacting with two different binding sites located on different macromolecules	408
V. Conclusion	409
References	410

19. Application Strategies for the Primary Structure–Activity Relationship Exploration 415

Camille G. Wermuth

I. Introduction	415
II. Preliminary Considerations	415
III. Hit Optimization Strategies	416
A. Some information about the target is available	417
B. No information about the target is available	418
C. The predominant objective is potency	418
D. The predominant objective is the establishment of SARs	419
E. The predominant objective consists of analog design	422
IV. Application Rules	422
A. Rule number one: the minor modification rule	422
B. Rule number two: the biological logic rule	423
C. Rule number three: the structural logic's rule	424
D. Rule number four: the right substituent choice	424
E. Rule number five: the easy organic synthesis (EOS) rule	425
F. Rule number six: eliminate the chiral centers!	425
G. Rule number seven: the pharmacological logic rule	426
References	426

Part IV Substituents and Functions: Qualitative and Quantitative Aspects of Structure–Activity Relationships 429

Section Editor: Han van de Waterbeemd

20. Substituent Groups 431

Patrick Bazzini and Camille G. Wermuth

I. Introduction	431
II. Methyl Groups	432
A. Effects on solubility	432
B. Conformational effects	434
C. Electronics effects	435
D. Effects on metabolism	437
E. Extensions to other small alkyl groups	440

III. Effects of Unsaturated Groups	441
A. Vinyl series	442
B. Allylic series	443
C. Acetylenic series	445
D. Cyclenic equivalents of the phenyl ring	447
IV. Effects of Halogenation	448
A. The importance of the halogens in the structure–activity relationship	448
B. Usefulness of the halogens and of cognate functions	451
V. Effects of Hydroxylation	452
A. Effects on solubility	453
B. Effects on the ligand–receptor interaction	453
C. Hydroxylation and metabolism	453
VI. Effects of Thiols and Other Sulfur-Containing Groups	454
A. Drugs containing thiol	454
B. Drugs containing oxidized sulfides	454
C. Drugs containing thiocyanate or thiourea	454
VII. Acidic Functions	456
A. Effects on solubility	456
B. Effects on biological activity	457
VIII. Basic Groups	458
IX. Attachment of Additional Binding Sites	459
A. To increase lipophilicity	459
B. To achieve additional interactions	459
References	460

21. The Role of Functional Groups in Drug–Receptor Interactions 464

Laurent Schaeffer

I. Introduction	464
II. General Principles	464
III. The Importance of the Electrostatic and Steric Match Between Drug and Receptor	465
A. Electrostatic interactions	465
B. Steric interactions	471
C. Enthalpy/entropy compensation	472
IV. The Strengths of Functional Group Contributions to Drug–Receptor Interactions	473
A. Measuring functional group contributions	473
B. The methyl group and other nonpolar substituents	475
C. The hydroxyl group and other hydrogen-bond forming substituents	476
D. Acidic and basic substituents	476
E. Practical applications for the medicinal chemist	476
F. Ligand efficiency	478
V. Cooperative binding	478
References	479

22. Compound Properties and Drug Quality 481

Christopher A. Lipinski

I. Introduction	481
II. Combinatorial Libraries	482
A. Library design for HTS screens	482
B. Experimental synthesis success rate	483
C. Poor solubility and library design	483
D. Importance of the synthesis rate-determining step	483
E. If protocol development is rate determining	484
F. Poor ADME properties – business aspects	484

G. If library production is rate determining	484
H. Relative importance of ADME assays	484
III. Chemistry Control of Intestinal Permeability	484
A. Improving permeability	485
B. Hydrogen bonding and permeability	485
C. Intramolecular hydrogen bonds	485
D. Permeability testing	485
IV. Chemistry Control of Aqueous Solubility	486
A. The definition of poor solubility	486
B. Aqueous solubility and blunt SAR	486
C. Changing the pK _a	486
D. Improving aqueous solubility	487
V. <i>In Vitro</i> Potency and Chemistry Control	487
A. Lead complexity	487
VI. Metabolic stability	488
A. ADME computational models	488
B. Limitations of Caco-2 cell culture	488
C. Poor aqueous solubility and permeability assay noise	489
D. Physiologically-relevant screening concentration	489
VII. Acceptable Solubility Guidelines for Permeability Screens	489
A. Batch-mode solubility prediction	490
References	490

23. Quantitative Approaches to Structure–Activity Relationships 491

Han van de Waterbeemd and Sally Rose

I. Introduction to QSAR	491
II. Brief History and Outlook	492
III. QSAR Methodology	493
A. Descriptors	493
B. Methods for building predictive models	496
C. Global and local models, and consensus modeling	503
D. Time-series behavior and autoQSAR	503
E. Experimental design	504
F. Inverse QSAR and multi-objective optimization	505
IV. Practical Applications	505
A. Limitations and appropriate use	505
B. Examples	506
C. Library design, compound acquisition and profiling	508
D. HTS analysis	509
E. Software	509
References	510

Part V Spatial Organization, Receptor Mapping and Molecular Modeling 515

Section Editor: David J. Triggle

24. Overview: The Search for Biologically Useful Chemical Space 517	
<i>David J. Triggle</i>	
I. Introduction	517
II. How Big is Chemical Space?	518
III. Biological Space is Extremely Small	518
IV. Limited Biological Space as an Effective Biological Strategy	519
References	520

25. Pharmacological Space	521
<i>Andrew L. Hopkins</i>	
I. What is Pharmacological Space?	521
II. Chemical Space	521
A. Drug-like space	522
III. Target Space	524
A. Druggability	525
B. Structure-based druggability	526
C. Degrees of druggability	527
D. Druggable genome	529
VI. Conclusions	531
Acknowledgments	531
References	531

26. Optical Isomerism in Drugs	533
<i>Camille G. Wermuth</i>	
I. Introduction	533
II. Experimental Facts and Their Interpretation	533
A. Stereoselectivity in biologically active compounds	533
B. The three-point contact model	535
C. Diastereoisomers	537
D. Stereoselectivity ratios	537
E. Pfeiffer's rule	538
III. Optical Isomerism and Pharmacodynamic Aspects	538
A. Differences in potency and antagonism between two enantiomers	538
B. Differences in the pharmacological profile of two enantiomers	539
IV. Optical Isomerism and Pharmacokinetic Effects	539
A. Isomer effects on absorption and distribution	540
B. Isomer effects on metabolism	540
C. Isomer effects on uptake	541
D. Isomer effects on excretion	541
V. Practical Considerations	541
A. Racemates or enantiomers?	541
B. The distomer counteracts the eutomer	542
C. Racemic switches	542
D. The distomer is metabolized to unwanted or toxic products	542
E. Deletion of the chiral center	543
F. Usefulness of racemic mixtures	543
References	546

27. Multi-Target Drugs: Strategies and Challenges for Medicinal Chemists	549
<i>Richard Morphy and Z. Rankovic</i>	
I. Introduction	549
II. Strategies for Lead Generation	551
III. Main Areas of Focus in DML Discovery (1990–2005)	553
A. SERT-plus DMLs for depression	554
B. Dopamine D ₂ -plus DMLs for schizophrenia	555
C. DMLs targeting the angiotensin system for hypertension	555
D. Histamine H ₁ -plus DMLs for allergies	558
E. AChE-based DMLs for Alzheimer's disease	559
F. PPAR-based DMLs for metabolic disease	560
G. DMLs that inhibit multiple kinases for treating cancer	560

H. DMLs targeting the arachidonic acid cascade	561
I. Mu-opioid-plus DMLs for treating pain	563
IV. Optimization of the Activity Profile and Wider Selectivity	563
V. The Physicochemical Challenge	565
VI. Summary	568
References	569
28. Pharmacophore Identification and Pseudo-Receptor Modeling	572
<i>Wolfgang Sippl</i>	
I. Introduction	572
A. Historical background	573
B. Definitions	573
C. Importance of the pharmacophore concept	574
D. Application of pharmacophores	574
II. Methodology	575
A. Pharmacophore modeling	575
III. Advanced approaches	577
A. Structure-based pharmacophores	577
B. Pseudo-receptor models	579
IV. Application study	580
A. Pharmacophore-based screening for novel histamine H ₃ -receptor antagonists	580
B. Pharmacophore determination process	581
C. Pharmacophore-based screening of compound libraries	582
V. Conclusions	584
References	584
29. 3D Quantitative Structure–Property Relationships	587
<i>Thierry Langer and Sharon D. Bryant</i>	
I. Introduction	587
II. 3D QSAR Workflow	589
III. 3D QSAR: Conformation Analysis and Molecular Superimposition	590
IV. Calculation of 3D Molecular Field Descriptors	591
V. Statistical Tools	592
VI. Alignment Independent 3D QSAR Techniques	592
VII. Validation Of 3D QSAR Models	594
VIII. Applications	594
A. 3D QSAR study on the structural requirements for inhibiting AChE	594
B. 3D QSAR as a tool to determine molecular similarity	597
IX. Conclusions and Future Directions	601
References	601
30. Protein Crystallography and Drug Discovery	605
<i>Jean-Michel Rondeau and Herman Schreuder</i>	
I. Presentation	605
II. Historical Background	607
A. The early days of crystallography	607
B. The current state of the art	607
C. Past and present contributions to drug discovery	608
III. Examples	609
A. Aliskiren (Tekturna™, Rasilez™)	609
B. Nilotinib (Tasigna™)	610
IV. Basic Principles and Methods of Protein Crystallography	611
A. Crystallization	611

B. Data collection	615
C. From diffraction intensities to a molecular structure	615
D. Information content and limitations of crystal structures	618
V. Practical Applications	621
A. Target identification, selection and validation	621
B. Hit/lead generation	623
C. Lead optimization	627
References	629

Part VI Chemical Modifications Influencing the Pharmacokinetic Properties

Section Editor: Richard B. Silverman

635

31. Physiological Aspects Determining the Pharmacokinetic Properties of Drugs

637

Koen Boussey, Frans M. Belpaire and Johan Van de Voorde

I. Introduction	637
II. Passage of Drugs Through Biological Barriers	638
A. Transcellular drug transport	638
B. Paracellular drug transport	640
III. Drug Absorption	640
A. Dosage form of the drug	640
B. GI motility and gastric emptying	640
C. GI permeability to the drug	642
D. Perfusion of the GI tract and the first-pass effect	643
IV. Drug Distribution	644
A. Plasma protein binding	644
B. Drug accumulation	645
C. The blood–brain barrier	645
V. Drug Elimination	645
A. Excretion	645
B. Biotransformation	647
VI. Some Pharmacokinetic Parameters and Terminology	648
A. Plasma concentration–time curve	648
B. Volume of distribution	649
C. Clearance	650
D. Elimination half-life ($T_{1/2}$)	651
E. Bioavailability	651
VII. Variability in Pharmacokinetics	652
A. Genetic factors	652
B. Age	652
C. Drug interactions	653
D. Disease state	653
E. Pregnancy	653
Bibliography	654

32. Biotransformation Reactions and their Enzymes

655

Bernard Testa

I. Introduction	655
II. Functionalization Reactions	656
A. Enzymes catalyzing functionalization reactions	657
B. Reactions of carbon oxidation and reduction	660
C. Oxidation and reduction of N- and S-containing moieties	662
D. Reactions of hydration and hydrolysis	663

III.	Conjugation Reactions	664
	A. Introduction	664
	B. Methylation	665
	C. Sulfonation	665
	D. Glucuronidation	665
	E. Acetylation	667
	F. Conjugation with coenzyme A and subsequent reactions	668
	G. Conjugation reactions of glutathione	669
IV.	Biological Factors Influencing Drug Metabolism	671
V.	Concluding Remarks	672
	References	672
33.	Biotransformations Leading to Toxic Metabolites: Chemical Aspects	674
	<i>Anne-Christine Macherey and Patrick M. Dansette</i>	
I.	Historical Background	674
II.	Introduction	675
III.	Reactions Involved in the Bioactivation Process	676
	A. Oxidation	676
	B. Oxidative stress	678
	C. Reduction	680
	D. Substitutions: hydrolysis and conjugation	682
	E. Eliminations	683
	F. Further biotransformations leading to the ultimate toxicant	683
IV.	Examples of Metabolic Conversions Leading to Toxic Metabolites	685
	A. Acetaminophen	685
	B. Tienilic acid	687
	C. Halothane	688
	D. Valproic acid	690
	E. Troglitazone	691
V.	Conclusion	693
	References	694
34.	Drug Transport Mechanisms and their Impact on the Disposition and Effects of Drugs	697
	<i>Jean-Michel Scherrmann</i>	
I.	Introduction	697
II.	Biology and Function of Transporters	698
	A. Modes of active transport	698
	B. Genes and classification	698
	C. Basic structure	699
	D. Distributions and properties of transporters in tissues	699
III.	Transporters in Drug Disposition	702
	A. ABC transporters	702
	B. SLC transporters	703
IV.	Roles of Transporters in Drug Pharmacokinetics, Pharmacodynamics and Toxicology	705
	A. Intestinal absorption	705
	B. Liver and hepatic clearance	706
	C. Blood barriers and tissue distribution	707
	D. Kidney and renal clearance	707
V.	Conclusion	709
	Acknowledgments	709
	References	709

35. Strategies for Enhancing Oral Bioavailability and Brain Penetration	711
<i>Brian C. Shook and Paul F. Jackson</i>	
I. Introduction	711
II. Enhancing Oral Bioavailability	711
A. Metabolic stability	711
B. Structural rigidity	712
C. pK_a	713
D. Hydrogen bond interactions	713
E. Miscellaneous	715
III. Enhancing Brain Penetration	715
A. Metabolic stability	715
B. pK_a	716
C. Log P	717
D. Hydrogen bond interactions	718
IV. Conclusion	719
References	719
36. Designing Prodrugs and Bioprecursors	721

Camille G. Wermuth

I. Introduction	721
II. The Different Kinds of Prodrugs	721
A. Definitions and classifications	721
B. The carrier prodrug principle	722
C. The bioprecursor-prodrug principle	723
D. Other categories of prodrugs	724
E. Practical applications of prodrug design	724
III. Carrier Prodrugs: Application Examples	724
A. Improvement of the bioavailability and the biomembrane passage	724
B. Site-specific delivery	728
C. Prolonged duration of action	730
IV. Particular Aspects of Carrier Prodrug Design	731
A. Use of cascade prodrugs	731
B. Codrugs	734
C. Soft drugs	734
D. Carrier prodrugs: conclusion	734
V. Bioprecursor Prodrugs: Application Examples	735
A. Oxidative bioactivations	735
B. Reductive bioactivations	737
C. Mixed bioactivation mechanism	738
D. Reactions without change in the state of oxidation	740
VI. Discussion	740
A. Bioprecursors versus carrier prodrugs	740
B. Existence of mixed-type prodrugs	740
VII. Difficulties and Limitations	741
VIII. Conclusion	742
References	742

Part VII Pharmaceutical and Chemical Means to Solubility and Formulation Problems

Section Editor: Michael J. Bowker

747

37. Preparation of Water-Soluble Compounds through Salt Formation	749
<i>Michael J. Bowker and P. Heinrich Stahl</i>	
I. Introduction	749
II. The Solubility of Compounds in Water	750

A.	The determination and prediction of solubility	750
B.	Ionization of drugs and the importance of pK_a	751
III.	Acids and Bases Used in Salt Formation	751
IV.	Early salt formation studies	753
A.	Choice of salt formers	753
B.	Prediction of the pH of the salt in solution	754
C.	Search for crystalline salts	755
V.	Comparison of Different Crystalline Salts	755
A.	Melting point	756
B.	Aqueous solubility	756
C.	Common ion and indifferent electrolyte effects	758
D.	Hygroscopicity	758
E.	Solubility in co-solvents (water-miscible solvents)	759
F.	Dissolution Rate	759
G.	Particle size and crystal morphology	760
H.	Polymorphism and pseudopolymorphism	760
I.	Chemical stability	761
J.	Other properties	761
VI.	Implications of Salt Selection on Drug Dosage Forms	762
A.	Tablet products	762
B.	Hard gelatine capsules	763
C.	Parenteral solutions	763
D.	Oral solutions	763
E.	Suspension formulations	763
F.	MDI products	764
G.	DPI products	764
H.	Soft gelatine capsule formulations	764
I.	Emulsions, creams and ointments	764
VII.	Conclusion	765
	References	765

38. Preparation of Water-Soluble Compounds by Covalent Attachment of Solubilizing Moieties 767

Camille G. Wermuth

I.	Introduction	767
II.	Solubilization Strategies	768
A.	How will the solubilizing moiety be grafted?	768
B.	Where will it be grafted?	768
C.	What kind of solubilizing chain will be utilized?	768
III.	Acidic Solubilizing Chains	769
A.	Direct introduction of acidic functions	769
B.	Alkylation of OH and NH functions with acidic chains	769
C.	Acylation of OH and NH functions with acidic chains	770
IV.	Basic Solubilizing Chains	775
A.	Direct attachment of a basic residue	775
B.	Bioisosteric exchange of a basic functionality	776
C.	Development of a water-soluble prodrug of diazepam	776
D.	Attachment of the solubilizing moiety to an alcoholic hydroxyl	777
E.	Attachment of the solubilizing moiety to an acidic NH function	779
F.	Attachment of the solubilizing moiety to a basic NH_2 function	779
G.	Attachment of the solubilizing moiety to carboxylic acid functionalities	780
V.	Non-ionizable Side Chains	780
A.	Glycolyl and glyceryl side chains	780
B.	Polyethylene glycol derivatives	781
C.	Glucosides and related compounds	781

VI. Concluding Remarks	782
References	783
39. Drug Solubilization with Organic Solvents, or Using Micellar Solutions or Other Colloidal Dispersed Systems	786
<i>Michael J. Bowker and P. Heinrich Stahl</i>	
I. Introduction	786
II. Factors Controlling Solubility and Absorption	788
A. The nature of drug substances	788
B. The polarity of the solvent system	788
III. Water–cosolvent systems	789
IV. Solubilization Mediated by Surfactants	793
V. Solubilization by Lipid Vehicles	798
A. Emulsions and microemulsions	798
B. Liposomes	802
VI. Nanoparticles and Other Nanocolloidal Technologies	803
VII. Drug Delivery and Clearance Mechanisms of Nanocolloids	806
VIII. Drug Delivery and Accumulation Using Colloidal Systems for the Treatment of Cancer	807
A. Liposome formulations	807
B. Formulations based on nanoparticles, microparticles and conjugated systems	808
IX. Modification of Drug Toxicity by Nanocolloidal Drug Delivery Systems	808
References	809
40. Improvement of Drug Properties by Cyclodextrins	813
<i>Kaneto Uekama and Fumitoshi Hirayama</i>	
I. Introduction	813
II. Pharmaceutically Useful CyDs	813
A. Physicochemical profiles of CyDs	814
B. Biological profiles of CyDs	814
III. Improvement of Drug Properties	816
A. Solubilization	817
B. Stabilization in solution	818
C. Control of solid properties	819
D. Release control	821
E. Enhancement of drug absorption	822
F. Reduction of side-effects	824
G. Use in peptide and protein drugs	826
H. Combined use of CyDs with additives	829
IV. CyD-Based Site-Specific Drug Delivery	831
A. Colon targeting	832
B. Cell targeting	834
C. Brain targeting	835
V. Conclusion	835
References	835
41. Chemical and Physicochemical Approaches to Solve Formulation Problems	841
<i>Camille G. Wermuth</i>	
I. Introduction	841
II. Increasing Chemical Stability	841
III. Improved Formulation of Peptides and Proteins	844
IV. Dealing with Mesomorphic Crystalline Forms	845
V. Increasing the Melting Point	846
A. Salt or complex formation	846
B. Covalent derivatives	846

C. Introduction of symmetry	847
VI. Gastrointestinal Irritability and Painful Injections	847
A. Gastrointestinal irritability	847
B. Avoidance of painful injections	848
VII. Suppressing Undesirable Organoleptic Properties	849
A. Odor	849
B. Taste	850
References	852

Part VIII Development of New Drugs: Legal and Economic Aspects

Section Editor: Bryan G. Reuben

855

42. Discover a Drug Substance, Formulate and Develop It to a Product 857

Bruno Galli and Bernard Faller

I. Introduction	857
II. Discover the Drug Substance	857
A. Exploratory research (target finding)	858
B. Early discovery program (lead finding)	858
C. Mature discovery program (lead optimization)	858
D. Research–development interface	859
E. Learning experiences	859
III. Defining Experimental Formulations, The Creative Phase	859
A. Basic thoughts on oral formulation	859
B. What is the purpose of a formulation?	859
C. Suggested sequence of activities prior to start formulation	860
D. Biopharmaceutical classification of compounds	861
E. How do we proceed at a practical level?	861
F. Which formulation principles are used?	862
IV. Pharmaceutical Development in Industry	863
V. Fixing The Quality And Develop The Product in A Regulated Environment	865
References	866

43. Drug Nomenclature 867

R. G. Balocco Mattavelli, J.C. Dong, S. Lasseur and S. Kopp

I. Introduction	867
II. Trade Names and Nonproprietary Names	867
III. Drug Nomenclature	868
A. INNs for pharmaceutical substances	868
B. Common names selected by the International Standards Organization (ISO)	874
IV. Use and Protection of Nonproprietary Names	874
A. Use of nonproprietary names	874
B. Protection of nonproprietary names	874
V. Summary	875
References	875
Annex	875

44. Legal Aspects of Product Protection: What a Medicinal Chemist Should Know about Patent Protection 878

Maria Souleau

I. Introduction	878
A. History of the patent-system prior to 1883	878
B. Main conventions and treaties	879

II. Definition of A Patent – Patent Rights	882
III. Kind of Inventions	882
IV. Subjects of Patents: Basic and Formal Requirements for Filing a Patent	882
A. Basic requirements	882
B. Formal requirements	888
V. Lifetime of Patents	890
VI. Ownership of Patents	890
VII. Infringement of a Patent	890
VIII. Patents as a Source of Information	891
IX. Patenting in the Pharmaceutical Industries	891
X. Conclusion	892
References	892

45. The Consumption and Production of Pharmaceuticals 894

Bryan G. Reuben

I. “Important” Drugs	895
A. The top-earning drugs	895
B. The most widely prescribed drugs	895
C. National differences in prescribing	899
II. Sources of Drugs	902
A. Vegetable sources	902
B. Animal sources	902
C. Biological sources	902
D. Fermentation	903
E. Chemical synthesis	903
III. Manufacture of Drugs	903
A. Good manufacturing practice	904
B. Plant design	904
C. Formulation and packaging–sterile products	905
D. Choice of reagents	906
E. “Green” chemistry	906
F. Downstream processing	907
G. Outsourcing	907
IV. Social and Economic Factors	909
A. Pattern and cost of innovation	909
B. Patents	910
C. Orphan drugs	911
D. Generic pharmaceuticals	912
E. Parallel trade	914
F. Cost containment measures	914
G. Pharmacoeconomics	916
V. The Future of the Pharmaceutical Industry	918
A. Trends in pharmaceuticals	919
B. Conclusion	920
References	920

Index 923